2012
DOI: 10.1182/blood-2011-12-395707
|View full text |Cite
|
Sign up to set email alerts
|

Anti-CD20 (rituximab) therapy for anti–IFN-γ autoantibody–associated nontuberculous mycobacterial infection

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
133
0

Year Published

2012
2012
2024
2024

Publication Types

Select...
5
2
1

Relationship

2
6

Authors

Journals

citations
Cited by 163 publications
(134 citation statements)
references
References 27 publications
1
133
0
Order By: Relevance
“…Although antibody levels may decrease with disease quiescence, they can persist for years. 30 Therefore, it remains unknown whether the autoantibody-negative patients with disseminated opportunistic infections that had resolved had another underlying disorder or whether anti–interferon-γ autoantibodies can resolve completely.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Although antibody levels may decrease with disease quiescence, they can persist for years. 30 Therefore, it remains unknown whether the autoantibody-negative patients with disseminated opportunistic infections that had resolved had another underlying disorder or whether anti–interferon-γ autoantibodies can resolve completely.…”
Section: Discussionmentioning
confidence: 99%
“…Since many patients with anti–interferon-γ autoantibodies remain actively infected despite antimicrobial therapy, this observation suggests that therapeutic targeting of anti–interferon-γ autoantibodies may warrant investigation. 5,30 …”
Section: Discussionmentioning
confidence: 99%
“…Although the mechanism of antibody production and the acquisition of neutralizing capacity remain unknown, some reports have speculated on the association between the antibody and NTM infection. Two groups from the USA reported the utility of rituximab against disseminated NTM in patients with anti-IFN-g autoantibodies [4,5]. The subjects went into remission along with reduction in the concentration or neutralizing capacity of anti-IFNg autoantibodies as a consequence of rituximab administration.…”
Section: Discussionmentioning
confidence: 99%
“…In most cases, the causative agents of disseminated NTM include Mycobacterium avium complex (MAC) and rapid-growing mycobacteria [1e3]. The concentration or neutralizing capacity of anti-IFN-g autoantibodies was reduced after the initiation of anti-mycobacterial agents and rituximab in a few cases [4,5]. A case of disseminated Mycobacterium gordonae and Mycobacterium mantenii in a patient with anti-IFN-g autoantibodies is described.…”
Section: Introductionmentioning
confidence: 99%
“…; STAT1 phosphorylation index: 47, control 407) was identified in the serum using an enzymelinked immunosorbent assay (ELISA), although the trigger for the production of anti-IFN-γ autoantibodies remains unidentified. While the antibody titers may decrease in association with the amelioration of disease, it has also been reported that elevated titers can persist for years (6).…”
Section: Introductionmentioning
confidence: 99%